4093 results about "Blood serum" patented technology

The invention discloses a xanthine oxidase inhibitory peptide with a kidney improving function and application thereof, and belongs to the technical field of biological medicines.The xanthine oxidase inhibitory peptide is screened out by conducting enzymolysis, separation and purification on litopenaeus vannamei processing by-products and utilizing a molecular docking technology, the amino acid sequence of the xanthine oxidase inhibitory peptide is Pro-Leu-Gly-Pro-Pro-Pro, and the amino acid sequence of the xanthine oxidase inhibitory peptide is Pro-Leu-Gly-Pro-Pro-Pro. And the half inhibition concentration of the polypeptide is 2.356 + / -0.2448 mM. The xanthine oxidase inhibitory peptide is proved to have an improvement effect on hyperuricemia mice, the improvement effect is mainly characterized by reducing the content of serum uric acid, creatinine and urea nitrogen of the hyperuricemia mice, inhibiting the activity of xanthine oxidase (XOD) in serum and livers of the mice, inhibiting synthesis of uric acid and improving kidney injury of the mice, and Toxinpred prediction shows that the xanthine oxidase inhibitory peptide has the effect of inhibiting the activity of xanthine oxidase (XOD) in the serum and livers of the mice. The xanthine oxidase inhibitory peptide is free of toxic and side effects, so that the xanthine oxidase inhibitory peptide has a wide application prospect in preparation of food or drugs for improving renal functions.

The invention discloses a xanthine oxidase inhibitory peptide with uric acid reducing activity and application thereof, and belongs to the technical field of biological medicines.The xanthine oxidase inhibitory peptide is obtained by conducting enzymolysis, separation and purification on processing byproducts such as litopenaeus vannamei heads and shells with xanthine oxidase inhibitory activity. The xanthine oxidase inhibitory peptide is screened by using a molecular docking technology, and the amino acid sequence of the xanthine oxidase inhibitory peptide is Pro-Pro-Val-Pro-Pro-Pro. The xanthine oxidase inhibitory peptide has an XOD (X-Oxidase) half inhibitory concentration of 3.181 + / -0.1786 mM. The invention further proves that the xanthine oxidase inhibitory peptide has a certain improvement effect on hyperuricemia mice, and the xanthine oxidase inhibitory peptide mainly has the effects of reducing the content of serum uric acid, creatinine and urea nitrogen of the hyperuricemia mice, inhibiting the activity of xanthine oxidase (XOD) in serum and liver of the mice, inhibiting synthesis of uric acid and improving kidney injury of the mice, and the xanthine oxidase inhibitory peptide has a certain improvement effect on the hyperuricemia mice through Toxinpred prediction. The xanthine oxidase inhibitory peptide uric acid reducing peptide is free of toxic and side effects and has a wide market application prospect.

The invention relates to a construction method of a metabolic syndrome phlegm syndrome lipid metabolism characteristic diagnosis model. The construction method comprises the following steps: S1, acquiring a serum sample; s2, carrying out lipid metabolite analysis through a full-quantitative lipidomics formula; s3, carrying out primary screening on differential metabolites; s4, optimizing the characteristic indexes by using a random forest algorithm and stepwise regression; and S5, constructing a differential metabolite diagnosis model through Logistic regression analysis. By analyzing differential lipid metabolites of patients with MetS phlegm syndromes and non-phlegm syndromes, the invention reveals that abnormal accumulation of lipid and lipid metabolites may be the core pathological parenchyma of MetS phlegm syndromes. By integrating lipid metabonomics data, using a random forest algorithm, stepwise regression and other methods to screen feature difference lipid metabolites and construct a MetS phlegm syndrome specific diagnosis model, a novel combined biomarker and evidence-based basis are provided for early diagnosis of MetS phlegm syndromes, and a scientific basis can also be provided for objective diagnosis of traditional Chinese medicine phlegm syndromes.

The invention belongs to the technical field of biological medicine, and discloses a probiotic agent capable of improving the physiological activity function of vitamin D and maintaining bone health and application of the probiotic agent. The invention provides a probiotic agent composed of bifidobacterium adolescentis and bifidobacterium longum, the probiotic agent can significantly improve the bone mineral density, the bone trabecula thickness, the bone trabecula number, the bone trabecula connectivity and the bone volume fraction of an osteoporosis mouse, and meanwhile, the bone trabecula separation degree of the osteoporosis-removed mouse is significantly reduced; the level of vitamin D metabolites such as 25-hydroxy vitamin D and 1, 25-dihydroxy vitamin D in mouse serum is improved; the content of serum calcium and alkaline phosphatase in serum of mice is reduced, and the level of osteocalcin and type I procollagen amino terminal peptide in the serum is improved. The probiotic agent can relieve bone calcium loss, maintain bone health, repair bone injury, increase osteoblasts and reduce the osteoporosis degree, and can be used for preparing drugs for preventing and / or treating osteoporosis or preparing health care products or food beneficial to improving bone mineral density.

The invention discloses a bacterial polypeptide Gfo and application thereof in preparation of rheumatoid arthritis diagnosis products, and belongs to the technical field of rheumatoid arthritis diagnosis. The amino acid sequence of the bacterial polypeptide Gfo is LNSHGFLPETE. A diagnostic product prepared from the bacterial polypeptide Gfo can effectively detect that the level of an anti-bacterial polypeptide Gfo antibody in a biological sample of a rheumatoid arthritis patient is obviously higher than that of healthy people and other rheumatoid immune diseases similar to rheumatoid arthritis. In addition, in CCP antibody and RF negative patients, the increase is still significant. Therefore, the antibacterial polypeptide Gfo antibody is an important biomarker of rheumatoid arthritis, and provides an effective new method for diagnosis of RA, especially diagnosis of serum-negative RA.

The invention provides a strain of lactobacillus plantarum YS-AG23 with high antioxidant activity, and a rhizoma polygonati and radix angelicae sinensis fermented product obtained by fermenting rhizoma polygonati and radix angelicae sinensis with the strain of lactobacillus plantarum YS-AG23. In a D-galactose induced premature ovarian failure mouse model, the fermentation product can regulate up the levels of antioxidant and stress protection genes SOD2 and HO-1 and an anti-aging gene SIRT1 by regulating down the expression of a key gene AGER of an inflammation and oxidative stress pathway, so that the oxidative stress and inflammatory response of model mouse ovarian tissues are remarkably reduced; meanwhile, the serum hormone level can be specifically adjusted, the serum estradiol (E2) level can be increased, the follicle stimulating hormone (FSH) and luteinizing hormone (LH) levels can be reduced to be close to the normal range, the expression of anti-mullerian hormone (AMH) and hormone regulatory gene LHR of ovarian reserve markers can be up-regulated, the proliferative activity and estrogen secretion function of follicular granulosa cells can be improved, and the effect of preventing ovarian reserve is achieved. The wet weight of atrophic uterus and ovary of the model mouse is remarkably increased, uterine and ovary atrophy is effectively reversed, and the ovarian reserve function of the D-galactose induced premature ovarian failure model mouse is recovered. Besides, in an H2O2-induced human dermal fibroblast aging model, the yeast can improve the activity of aging cells in a concentration-dependent manner and reduce the level of reactive oxygen species (ROS) in the cells; in addition, by up-regulating the expression of a collagen synthesis key gene COL1A1 and down-regulating the expression of a cell senescence marker gene p16, skin cell senescence caused by oxidative stress can be effectively improved. In conclusion, the polygonatum sibiricum and angelica sinensis leavening can synchronously improve premature ovarian failure and skin cell senescence caused by oxidative stress by accurately regulating and controlling oxidative stress, inflammatory response and tissue function related genes, and has wide application potential.

The present invention discloses an interfering RNA for inhibiting PCSK9 gene and use thereof. The interfering RNA comprises a nucleotide sequence set forth in any one or two or more of SEQ ID NOs: 1-40, 73-96. The interfering RNA of the present invention can better target and silence hepatic PCSK9 mRNA, reduce the protein level of PCSK9, enhance LDL-C metabolism, and reduce serum cholesterol, providing a solid technical foundation for the development of siRNA medicaments for the prevention, treatment, and symptom alleviation of PCSK9 gene-mediated diseases.

The invention provides a compound probiotic for relieving anxiety behaviors and application of the compound probiotic. The compound probiotic comprises bifidobacterium animalis YRK-12 (the preservation number is CGMCC (China General Microbiological Culture Collection Center) NO.28597) and lactobacillus rhamnosus LRa-Y8 (the preservation number is CGMCC NO.34186). The invention finds that the two bacteria are compounded and can be matched and promoted with each other, and have a synergistic effect on the aspect of preventing and treating anxiety disorder, which is specifically shown as follows: the reduction of center lattice movement time and percentage caused by LPS (Lipopolysaccharide) is relieved; the increase of mouse serum proinflammatory cytokines caused by LPS is improved; the increase of mouse brain tissue proinflammatory cytokines caused by LPS is improved. Under the condition that the using amount of the bacteria is consistent, the effect of the compounding of the two bacteria on improving the anxiety-like behavior induced by the LPS is obviously improved. Meanwhile, the two bacteria are probiotics, so that the product is safe and is not easy to generate resistance.

The invention belongs to the technical field of biological detection, and particularly relates to a monoclonal antibody 1D3 for detecting a porcine epidemic diarrhea virus antibody and application of the monoclonal antibody 1D3. The CDR sequences of the heavy chain variable region are respectively shown as SEQ ID NO.1-3, and the CDR sequences of the light chain variable region are respectively shown as SEQ ID NO.4-6. The antibody can specifically recognize PEDV / S1 protein, binding of the antibody can be competitively blocked by a PEDV specific neutralizing antibody in serum, and the antibody is suitable for establishing a blocking ELISA method. A detection tool based on the antibody has high specificity and sensitivity, and the blocking rate to PEDV positive serum is higher than 50%. The invention can be used for preparing a detection kit or evaluating the immune effect of a vaccine, and provides an efficient and accurate technical means for PEDV infection diagnosis and immune monitoring.

The invention discloses bifidobacterium animalis and application thereof in allergic rhinitis products, and belongs to the technical field of microorganisms. The technical problem to be solved is that the existing common allergic rhinitis treatment means cannot meet the requirements of patients on safety, long-acting effect and treatment cycle. The invention provides an animal bifidobacterium subsp. Lactis Def +, and after an effective dose of animal bifidobacterium subsp. Lactis Def + is applied to a subject, the animal bifidobacterium subsp. Lactis Def + is found to be capable of remarkably relieving the allergic rhinitis symptom. Specifically, the symptoms of sneezing, dry nose and rhinocnesmus are reduced; the number of nasal septum mucosa intrinsic layer inflammation infiltration cells and nasal septum mucosa epithelium pathological changes are reduced; the IgA and IgE levels of serum are reduced; the levels of proinflammatory factors IL-4, IL-5 and IL-13 are reduced; the normal spleen index is maintained; the imbalance state of Th1 / Th2 and Th17 / Treg is effectively improved, and the body immunity is improved; a safe and long-acting scheme is provided for allergic rhinitis diseases.

The invention discloses an interfering RNA (Ribonucleic Acid) for inhibiting a PCSK9 gene and application of the interfering RNA. The interfering RNA comprises any one or more than two nucleotide sequences as shown in SEQ ID NO: 1-40 and SEQ ID NO: 73-96. The interfering RNA can better target and silence mRNA of the liver PCSK9, reduce the protein level of the PCSK9, enhance LDL-C metabolism and reduce serum cholesterol, and a solid technical basis is provided for research and development of siRNA drugs for prevention and treatment of PCSK9 gene mediated diseases and symptom relief.

The invention discloses a sugar chain marker combination for predicting prognosis of liver cancer transarterial chemoembolization and application of the sugar chain marker combination. The invention discovers and verifies that the combination composed of NA3Fb, NA4Fb and NA4F2b can be used as a novel marker for evaluating TACE treatment reaction and prognosis by analyzing a serum sugar chain map of a liver cancer patient for the first time. Based on the marker combination, a TACE-GT prognosis scoring model and system are established, and the progression risk of a patient within 12 months after a TACE operation can be effectively distinguished by noninvasively detecting the expression levels of three carbohydrate chains in serum of the patient and calculating a specific score. The detection method provided by the invention is based on a blood sample, and has the advantages of noninvasiveness and convenience, and a risk assessment system can provide individualized curative effect prediction and decision support for clinicians before and after TACE treatment, and has important values for realizing precise treatment of liver cancer and improving prognosis of patients.

The invention discloses a post-stroke depression risk prediction system based on cerebral small vascular diseases and inflammatory markers, and relates to the technical field of computer-aided engineering, the post-stroke depression risk prediction system comprises: a data acquisition module acquires CSVD image data, serum inflammatory markers and clinical baseline information; the data preprocessing module processes image denoising registration, fills up marker missing values and encodes clinical information; the CSVD feature extraction module extracts image omics features and quantifies severity; the inflammation marker module calculates statistical characteristics and inflammation intensity; the multi-dimensional fusion module integrates features and eliminates redundancy; the risk prediction module is trained by using an improved attention CNN-LSTM model; the result output module visualizes risk and intervention suggestions; the model dynamic optimization module updates parameters by incremental learning. According to the method, multi-source key data are integrated, the prediction accuracy and generalization ability are improved, clinical interpretation and dynamic adaptability are achieved, early recognition of post-stroke depression is assisted, and patient prognosis is improved.

The invention discloses a cord blood-derived regulatory T cell amplification culture medium and a use method thereof, and relates to the field of animal cell culture and immune cell therapy, the culture medium is a serum-free culture medium, the culture medium is composed of a basic culture medium, a serum substitute combination, a combination of four cell factors, an immunosuppressor, an apparent stabilizer and an antioxidant, and all the components play a role synergistically; according to the use method, cell amplification is realized through a collaborative process of staged environmental regulation and targeted activation. According to the method, the problems of exogenous pollution and batch difference caused by dependence of a serum-containing system on cord blood-derived regulatory T cell amplification in the prior art are solved, the defect that a serum-free scheme is difficult to consider the amplification efficiency and the function stability at the same time is overcome, the cell amplification quality and the clinical application safety are guaranteed, and the method is suitable for large-scale clinical transformation requirements.

The invention belongs to the technical field of liquid chromatography-mass spectrometry detection pretreatment, and particularly relates to a pretreatment method for liquid chromatography-tandem mass spectrometry analysis of pesticide and veterinary drug residues in serum, which comprises the following steps: (S1) carrying out heating reaction on Sc (III) salt, Cu (II) salt and 1H-pyrazole-4-formic acid (H2PyC) in a polar aprotic solvent, and cooling to obtain a green crystal, namely MOF-919; the chemical formula of the MOF-919 is [Sc < 3 > (mu3-O) (OH) < 3 >] [Cu3 (mu3-O) (mu-PyC) < 3 > (H2O) < 6 >] < 2 >; (S2) mixing the serum sample with an acetonitrile solution containing formic acid, carrying out ultrasonic treatment, vortex oscillation and centrifugation, taking supernate, and diluting the supernate with an aqueous solution containing formic acid to obtain a to-be-purified solution; and (S3) adding MOF-919 into the to-be-purified liquid, mixing, performing ultrasonic treatment, performing vortex oscillation, centrifuging, and taking supernate, thereby completing the pretreatment of the to-be-purified liquid. According to the method, the MOF-919 is used for adsorbing chemical pollutant residues in serum, especially phospholipids, so that the purpose of removing the chemical pollutant residues in blood is achieved. The method is simple and convenient to operate, small in organic solvent consumption and good in purification effect, and can be widely applied to residue analysis of chemical pollutants in serum.

The invention discloses bifidobacterium longum subsp.infantis capable of promoting bone growth and a metagen thereof, and belongs to the technical field of biology. The bifidobacterium longum subsp. Infantis CCFM1445 provided by the invention can promote the increase of bone volume fraction, femoral bone trabecula thickness and far-end growth plate thickness of mammals in a growth period, reduce the levels of serum bone resorption markers I-type collagen amino-terminal peptide and tartrate-resistant acid phosphatase, improve the levels of serum bone alkaline phosphatase and parathyroid hormone, and improve the clinical application value of the bifidobacterium longum subsp. Infantis CCFM1445. And the relative abundance of the other bacteria in the intestinal flora and the levels of creatine and indole-3-lactic acid are increased. The thermally inactivated bifidobacterium longum subsp. Infantis CCFM1445 can promote the increase of the volume fraction of femoral bones and the number of bone trabecula of malnourished mice and improve the N-terminal propeptide level of serum I-type procollagen. Therefore, the medicine or health care product prepared from the bifidobacterium longum subsp. Infantis CCFM1445 can be used for assisting in regulating bone metabolism and bone mass, and has a wide market prospect.

The present invention relates to the use of a pharmaceutical composition in the form of extended-release tablets containing Pirfenidone for treating NAFLD / NASH and advanced liver fibrosis by decreased serum cholesterol and triglycerides as well as reducing the content of hepatic fat accumulation, both in the form of macrosteatosis and microsteatosis. Additionally, its use as an agonist for PPARgamma (peroxisome proliferation receptor activated gamma), PPARalpha (peroxisome proliferation receptor activated alpha), LXR and CPT1, key molecules in the metabolism of fatty degradation and inflammation of the liver. In addition, another use is the induction of decreased expression of NFKB master gene, transcriptional inducer of hepatic inflammatory process factor. All of these events results in the reversal of NAFLD / NASH and advanced liver fibrosis.

The invention discloses a culture medium and application thereof, and a method for in-vitro separation culture and adipogenic differentiation of precursor adipocytes in goat muscle, and relates to the technical field of cell culture, the culture medium comprises the following components: 8-12 [mu] g / mL of insulin, 8-12% by volume of fetal calf serum, 95-105 U / mL of penicillin, 95-105 [mu] g / mL of streptomycin and the like. On the basis of the prior art, a proper amount of liquiritin and pilocarpine are mainly added into a culture medium, and synergistic cooperation of the liquiritin and pilocarpine is found, so that the adipogenic differentiation capacity of cells such as mesenchymal stem cells and precursor adipocytes is remarkably improved, and the application range is wide. On the basis, the invention also provides a complete set of perfect in-vitro isolated culture and adipogenic differentiation method of the goat intramuscular precursor adipocytes, and a method and a way are provided for a series of researches developed through the goat primary intramuscular precursor adipocytes in the future.

The invention belongs to the field of traditional Chinese medicines, and particularly relates to a traditional Chinese medicine composition for treating triple negative breast cancer and application thereof. The traditional Chinese medicine composition is prepared from the following main active ingredients in parts by mass: 20 to 40 parts of radix astragali seu hedysari, 10 to 20 parts of rhizoma curcumae, 10 to 20 parts of herba hedyotidis diffusae, 5 to 15 parts of fructus aurantii immaturus, 5 to 15 parts of radix bupleuri, 5 to 15 parts of radix paeoniae alba and 5 to 15 parts of liquorice root. Animal experiments show that the traditional Chinese medicine composition can significantly inhibit tumor growth and pulmonary metastasis of triple-negative breast cancer tumor-bearing mice, increase the proportion of CD8 + T lymphocytes in blood, reduce the proportion of MDSCs, significantly down-regulate the expression of pro-inflammatory cytokines such as IL-6, IL-1alpha, CXCL1 and GM-CSF in serum, and cooperate with PD-L1 immunotherapy to achieve a synergistic effect. And the whole blood and liver and kidney function indexes are in a normal range. Therefore, the traditional Chinese medicine composition disclosed by the invention can be used for effectively inhibiting the tumor growth and pulmonary metastasis of the triple negative breast cancer, remodeling the immune state of an organism and reducing the release of proinflammatory factors, and is safe, reliable, free of obvious liver and kidney toxicity and blood toxicity and small in side effect.

This invention belongs to the field of biodetection technology, specifically relating to a monoclonal antibody 1D3 for detecting porcine epidemic diarrhea virus (PEDV) and its applications. Its heavy chain variable region CDR sequences are SEQ ID NO. 1-3, and its light chain variable region CDR sequences are SEQ ID NO. 4-6. This antibody specifically recognizes the PEDV / S1 protein, and its binding can be competitively blocked by PEDV-specific neutralizing antibodies in serum, making it suitable for establishing a blocking ELISA method. Detection tools based on this antibody exhibit high specificity and sensitivity, with blocking rates exceeding 50% against PEDV-positive serum. This invention can be used to prepare detection kits or evaluate vaccine immunization efficacy, providing an efficient and accurate technical means for PEDV infection diagnosis and immune monitoring.

The invention belongs to the field of immunological detection, and provides a double-antibody sandwich ELISA kit for detecting the content of human beta-NGF. The enzyme-linked immunosorbent assay kit constructed by the invention is based on a double-antibody sandwich method, and is combined with a biotin-streptavidin signal amplification system and an enzyme developing amplification system, so that the detection sensitivity and specificity are greatly improved, and low-content samples can be accurately and quickly detected. The kit shows excellent stability and specificity and can be used for quantitatively detecting the content of beta-NGF in samples such as human serum, cell supernatant or tissue homogenate, so that an objective detection basis is provided for diagnosis, curative effect evaluation and pathogenesis research of related diseases.

The invention discloses a preparation process of crocodile penis peptide wine for improving kidney deficiency, and relates to the technical field of biology, the process comprises the steps of raw material pretreatment, collaborative graded enzymolysis, starter propagation, sand feeding, sand roughening, starter addition and stacking fermentation, distillation for wine taking and fine adjustment. Wherein the synergistic graded enzymolysis adopts a mixed enzymolysis technology, lecithin and phytic acid are added, and natural pH gradient is combined, so that the problems of wine precipitation and taste layering are effectively solved, and the product stability and the polypeptide retention rate are improved. Meanwhile, a traditional Chinese medicinal material compound formula is fused in the process, and the health-care effect is enhanced through the synergistic effect of enzymolysis and fermentation. The wine can significantly increase the content of testosterone in serum and the physical endurance, and improve the symptom of kidney deficiency. The method is mature in process, high in product quality and suitable for large-scale production.

The invention provides a liver tumor early diagnosis method and system based on artificial intelligence, and relates to the technical field of biomedical engineering, and the method comprises the steps: obtaining original information metadata related to the liver, the original information metadata comprises image data original information metadata and biomarker original information metadata, the image data comprises liver CT (computed tomography) and MRI (magnetic resonance imaging) image data, the biomarkers comprise serum tumor marker levels, and the physiological and environmental factors of the patients comprise age, gender, dietary habits and genetic backgrounds of the patients. According to the method, the problems that a tumor in a small and complex area is easily missed or misdiagnosed in the prior art are solved, the path density is predicted through denoising, segmentation and feature extraction of image data preprocessing in combination with a path simulation model based on a graph theory and a Monte Carlo simulation method, and a potential tumor area can be accurately judged.

The invention relates to the technical field of microorganisms, and discloses a lactobacillus delbrueckii subsp. Bulgaricus XJFY201503 and an application thereof in improving an immune function, the lactobacillus delbrueckii subsp. Bulgaricus XJFY201503 is preserved in the China General Microbiological Culture Collection Center (CGMCC), the preservation number is CGMCC NO.30047, and the preservation time is March 18, 2024. The lactobacillus delbrueckii subsp. Bulgaricus XJFY201503 can be used for directly improving the immune function of an immunosuppressive mouse by protecting and maintaining normal physiological structures of central and peripheral immune organs and promoting secretion of serum cytokines and immune globulins; and the immune function of the mouse can be indirectly promoted by relieving intestinal inflammation reaction.

The invention provides a cross-omics sparse feature selection system and method based on hierarchical causal modeling, and the system comprises a data input and preprocessing module which is used for receiving multi-omics original data of a multivariate sample; the hierarchical causal structure learning module is connected with the data input and adaptive preprocessing module and is used for constructing a cross-omics hierarchical causal topology; the causal-oriented sparse feature selection module is connected with the hierarchical causal structure learning module; and the model retraining and integration module is used for constructing a three-layer weighted integration discrimination model based on the screened markers, optimizing the fusion weight of each layer through a gradient descent algorithm, and outputting a final prediction result. According to the method, the protein-metabolism biological hierarchy relationship and serum-urine complementary information are fully utilized, and the method has good generalization ability and can be widely applied to marker mining and prediction modeling of cancers, metabolic diseases and the like, so that the accuracy and reliability of precise medical treatment are improved.

The invention provides bovine ephemeral fever virus positive serum as well as a preparation method and application thereof. The preparation method comprises the following steps: culturing bovine ephemeral fever virus by using MDBK suspension cells, inactivating by using beta-propiolactone, concentrating by using a 500kd hollow fiber column to obtain an antigen solution, and emulsifying the antigen solution and 61VG adjuvant according to a mass ratio of 1: 1.5 to prepare the vaccine; carrying out primary immunization and secondary immunization on the receptor, collecting blood of which the serum neutralizing antibody titer is greater than 1: 4096 14-21 days after the secondary immunization, and separating to obtain positive serum. The positive serum can be used for specific test, identification test and the like of the bovine ephemeral fever virus, can also be used for preparing related reagents, kits and standard substances, and provides efficient and normative technical support for prevention and control of bovine ephemeral fever.

The invention belongs to the technical field of biological medicines, and particularly relates to application of poecilobdella manillensis in preparation of a medicine for treating renal injury. The invention provides a new application of poecilobdella manillensis in preparation of a medicine for treating renal injury, serum biochemical index detection proves that the poecilobdella manillensis can effectively reduce serum creatinine and blood urea nitrogen levels, increase serum albumin and total protein content, remarkably improve glomerular filtration function and protein metabolism function, and improve renal function. And the improvement degree of the traditional Chinese medicine composition is superior to that of a traditional Chinese medicine contrast. Although the curative effect is slightly poorer than that of a chemical drug group, the safety advantage is remarkable. The poecilobdella manillensis can comprehensively regulate renal function metabolism indexes, relieve kidney injury and avoid common side effects of chemical drugs, provides a new choice for clinical treatment of kidney injury, and is especially suitable for chronic kidney disease patients needing long-term treatment.

The invention belongs to the field of antibody development, and discloses a screening method and application of a human-mouse protein high homologous target antibody based on a fully humanized antibody mouse. Aiming at the problem of weak antibody response caused by immune tolerance of human-mouse high homologous targets (protein homology is greater than or equal to 95%), the following scheme is provided: in embryonic stem cells (ES cells) of HUGO-Mabfully humanized antibody transgenic mice, a mouse target gene (such as ACVR2A) is knocked out through a Turbo Knockout technology, and homozygous knockout ES clones are screened; carrying out microinjection on the clones to the whitened B6 mouse blastocyst, and transplanting a pregnant mouse to obtain a Founder mouse; the Founder mouse is subjected to target antigen immunization for more than or equal to 4 times (the Freund's complete adjuvant is used for the first time), and the titer of the serum antibody is detected. According to the invention, 100% homozygous knockout chimeric efficiency is realized in the Founder stage, the mouse construction period is shortened from traditional 8-10 months to 3-4 months, and the diversity and affinity of the antibody are significantly improved (titer reaches 1: 729,000). The obtained antibody can be used for preparing medicines for treating tumors or autoimmune diseases.

The invention discloses a recombinant subunit vaccine for resisting trichomonas pigeonae infection and a preparation method of the recombinant subunit vaccine. The vaccine comprises two recombinant proteins with sequences as shown in SEQ ID NO: 7 and SEQ ID NO: 8 respectively and a pharmaceutically acceptable carrier. According to the invention, Sf9 cells are used for respectively expressing trichomonas pigeonae adhesion protein 33 and adhesion protein 65, the immunogenicity of the obtained recombinant protein is similar to that of natural protein, the expression level is high, the immunogenicity is strong, a very small amount of recombinant protein can provide a better immune protection effect, and the recombinant protein has no pathogenicity to pigeons, and can be used for preparing the recombinant protein for preventing and treating trichomonas pigeonae. Meanwhile, large-scale serum-free suspension culture can be carried out through a bioreactor, so that the vaccine production cost is greatly reduced.

The invention relates to the technical field of traditional Chinese medicines, in particular to a traditional Chinese medicine composition for treating rhinitis. The traditional Chinese medicine composition comprises platycodon grandiflorum, semen armeniacae amarae, citrus chachiensis hortorum, fructus aurantii, aster, ephedra, radices trichosanthis, thunberg fritillary bulb, liquorice and loquat leaves. The traditional Chinese medicine composition can be used for remarkably relieving sneezing symptoms caused by allergic rhinitis, reducing histamine and specific IgE levels in serum and improving the pathological change degree of nasal mucosa tissues, and has a wide application prospect.